The McGowan Institute has formed an alliance with the International Space Station (ISS) U.S. National Laboratory to develop and demonstrate the how micro-gravity can improve regenerative medicine-based therapies. The ISS provides a unique platform to conduct studies in a microgravity environment.
McGowan Institute for Regenerative Medicine Deputy Director Stephen Badylak, DVM, PhD, MD, a nationally recognized pioneer in stem cell and tissue regeneration, will receive BioMed SA’s 2019 Award for Innovation in Healthcare and Bioscience in San Antonio, Texas, September 19, 2019.
Patients with left-sided heart failure who get implanted devices to improve the pumping of their hearts may be more likely to develop heart failure on the opposite side of their hearts if they are pre-treated with off-label selective vasodilator drugs, according to new research published in Circulation: Heart Failure, an American Heart Association journal. McGowan Institute for Regenerative Medicine Deputy Director Robert Kormos, MD, FAHA, Professor of Cardiothoracic Surgery and Bioengineering at the University of Pittsburgh, past director of UPMC’s Artificial Heart Program, and the Brack G. Hattler Chair of Cardiothoracic Transplantation, is a co-author on this study.
Technology developed in the McGowan Institute Medical Devices Lab under the leadership of William Federspiel, PhD, William Kepler Whiteford Professor of Bioengineering, Chemical Engineering, and Critical Care Medicine has been incorporated into products for clinical use by ALung, a University of Pittsburgh spinout company. Dr. Federspiel is the Head of the Scientific Advisory Board and co-founder of ALung Technologies, Inc. The ALung devices are now being evaluated in several clinical trials. ALung is the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure.
McGowan Institute for Regenerative Medicine affiliated faculty member Joseph Glorioso III, PhD, Co-founder, CODA Biotherapeutics, and Professor and Emeritus Chair, Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, is working on a gene therapy approach for treating chronic pain. CODA is developing engineered neurotransmitter receptors that are activated exclusively by orally bioavailable drugs to control the activity of hyperexcitable neurons responsible for chronic neuropathic pain. The gene encoding the receptor is delivered to dysfunctional neurons by proprietary viral vectors that are optimized for robust and targeted gene transfer. Standard neurosurgical procedures are used to administer these viral vectors directly to the neurons to be controlled. Once expressed, the engineered receptor can be activated by the drug to modulate neuronal activity. This enables the selective, tunable and reversible regulation of the receptor – and hence cellular activity – based on the dosing regimen of the drug. CODA is engineering receptors to have exquisite sensitivity for the pharmacological activator, which should dramatically limit off-target side effects that plague many pharmaceutical treatments.
The McGowan Institute for Regenerative Medicine held its 2019 Scientific Retreat March 11-12, 2019. The focus was on peer-to-peer networking, and the retreat provided many opportunities to explore collaborative endeavors with other researchers, participating guests, and external partners who are working to bring regenerative medicine technologies to clinical use.
Congratulations to McGowan Institute for Regenerative Medicine deputy director Stephen Badylak, DVM, PhD, MD, professor in the Department of Surgery at the University of Pittsburgh and director of the Center for Pre-Clinical Tissue Engineering within the McGowan Institute, as his h-index (Scopus) has reached 100. The h-index is an author-level metric that attempts to measure both the productivity and citation impact of the publications of a scientist. The index is based on the set of the scientist’s most cited papers and the number of citations that they have received in other publications.
Julie Grant, reporting for Pittsburgh’s local CBS affiliate, KDKA, recently visited with McGowan Institute for Regenerative Medicine affiliated faculty member George Gittes, MD, Director of the Richard King Mellon Foundation Institute for Pediatric Research and Co-Scientific Director at UPMC Children’s Hospital of Pittsburgh of UPMC. She learned that reversing autoimmune type 1 diabetes without immunosuppression has proven to be extremely difficult, but Dr. Gittes and researchers at Children’s Hospital and the University of Pittsburgh School of Medicine have achieved that outcome in pre-clinical trials with an engineered, safe virus that does gene therapy.
One of the downsides to getting older is that skeletal muscle loses its ability to heal after injury. New research from the University of Pittsburgh implicates the so-called “longevity protein” Klotho, both as culprit and therapeutic target.
Mary Kekatos Health Reporter for the Dailymail.com and the Dailymail.com Reporter, recently detailed in her article that statins could prevent the spread of breast cancer, per a new study. Researchers say the drugs, which combat high cholesterol, do not prevent the cancer from occurring but stop it from spreading to other organs. Experiments performed in human cells and laboratory mice found that the pills prevent tumors from migrating to the lungs and liver.
ECM Therapeutics, Inc. has licensed multiple extracellular matrix (ECM) technologies developed in the laboratory of Stephen Badylak, DVM, PhD, MD (pictured top), including hydrogels, bioactive derivatives and methods for delivering these materials within the body. Dr. Badylak is a professor in the Department of Surgery, a deputy director of the McGowan Institute for Regenerative Medicine, and the director of the Center for Pre-Clinical Tissue Engineering within the Institute.
Sponsored by the Pittsburgh Business Times, the 2018 Health Care Hero Awards honor the individuals, companies, and organizations in western Pennsylvania for their contributions to improving health care in our region.
